March 21, 2025Market Update: Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note ~1 min.Bristol Myers Squibb (BMY) has seen a recent upswing in its stock price, but it still lags behind the overall market. Here are some key facts to consider about the company....
March 20, 2025Is Bristol-Myers Squibb the Most Undervalued Biotech Company? ~2 min.Recently, the European Commission (EC) has given its approval to Breyanzi, a novel treatment developed by Bristol-Myers Squibb (BMS) for Non-Hodgkin's Lymphoma (NHL)....
March 19, 2025Positive Development for Bristol-Myers Squibb Company's Breyanzi NHL Treatment ~1 min.Bristol-Myers Squibb Company's groundbreaking NHL treatment, Breyanzi, has received approval from the European Commission (EC) for its use in patients....
March 18, 2025Is Bristol-Myers Squibb Company BMY the Best Pharma Stock to Buy According to Hedge Funds ~1 min.Bristol-Myers Squibb Company (BMY) has gained the attention of hedge funds as the best pharmaceutical stock to invest in....
March 17, 2025Why Bristol-Myers Squibb Company BMY Went Down On Friday ~1 min.Bristol-Myers Squibb Company (BMY) experienced a decline in their stock price on Friday. The decrease can be attributed to factors such as market volatility and investor sentiment....
December 29, 2024Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials ~1 min.Bristol Myers Squibb (BMY) recently announced positive topline results from its Phase 3 trials evaluating Sotyktu deucravacitinib in adults with psoriatic arthritis....
December 29, 2024Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment ~1 min.Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors ...
February 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development ~1 min.Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....
January 5, 2025Regeneron Pharmaceuticals: A Strong Performer with Promising Financials ~2 min.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....
January 22, 2025Jim Sees Eli Lilly and Company LLY as a Long-Term Buy ~2 min.Eli Lilly and Company, a leading pharmaceutical company, has recently caught the attention of investors, including renowned analyst Jim....
